BACKGROUND: Atrophic body gastritis (ABG) is associated with both type I gastric carcinoids (T1-GCs) and intestinal-type gastric cancer. The occurrence of gastric cancer in ABG patients with type I gastric carcinoids has not yet been described. AIM: To describe the occurrence at follow-up of gastric cancer in ABG patients with type I gastric carcinoid in a retrospective case series in a single tertiary referral center. METHODS: Between 1994 and 2012, 17 new cases of T1-GCs were diagnosed among a cohort of ABG patients in a single tertiary referral center for ABG. The clinical charts of these 17 T1-GC patients were retrospectively evaluated for the occurrence of gastric cancer at follow-up (median 4.2 years, range 0.5-13). RESULTS: In 4 (23.5 %)/17 T1-GCs patients (3 females, age 40-78 years), gastric cancer occurred (median follow-up 5.9 years, range 5.1-13). Three cases were intestinal-type adenocarcinomas and one a signet-ring cell diffuse gastric cancer, localized in three cases in the antrum. In two patients, it was detected on random biopsies during follow-up gastroscopy; in the other two, gastroscopy was performed because of new symptoms. All patients with gastric cancer had associated autoimmune features (pernicious anemia, autoimmune thyroid disease and a spared antrum) compared to 77, 46 and 54 % of those without gastric cancer, although statistical significance was not reached. CONCLUSIONS: This case series shows that in patients with T1-GCs, gastric cancer may frequently occur at long-term follow-up. Thus, these patients should be monitored by a long-term surveillance program, including an accurate bioptic sampling of the antral mucosa.
BACKGROUND:Atrophic body gastritis (ABG) is associated with both type I gastric carcinoids (T1-GCs) and intestinal-type gastric cancer. The occurrence of gastric cancer in ABGpatients with type I gastric carcinoids has not yet been described. AIM: To describe the occurrence at follow-up of gastric cancer in ABGpatients with type I gastric carcinoid in a retrospective case series in a single tertiary referral center. METHODS: Between 1994 and 2012, 17 new cases of T1-GCs were diagnosed among a cohort of ABGpatients in a single tertiary referral center for ABG. The clinical charts of these 17 T1-GC patients were retrospectively evaluated for the occurrence of gastric cancer at follow-up (median 4.2 years, range 0.5-13). RESULTS: In 4 (23.5 %)/17 T1-GCs patients (3 females, age 40-78 years), gastric cancer occurred (median follow-up 5.9 years, range 5.1-13). Three cases were intestinal-type adenocarcinomas and one a signet-ring cell diffuse gastric cancer, localized in three cases in the antrum. In two patients, it was detected on random biopsies during follow-up gastroscopy; in the other two, gastroscopy was performed because of new symptoms. All patients with gastric cancer had associated autoimmune features (pernicious anemia, autoimmune thyroid disease and a spared antrum) compared to 77, 46 and 54 % of those without gastric cancer, although statistical significance was not reached. CONCLUSIONS: This case series shows that in patients with T1-GCs, gastric cancer may frequently occur at long-term follow-up. Thus, these patients should be monitored by a long-term surveillance program, including an accurate bioptic sampling of the antral mucosa.
Authors: L Vannella; E Lahner; J Osborn; C Bordi; M Miglione; G Delle Fave; B Annibale Journal: Aliment Pharmacol Ther Date: 2010-02-18 Impact factor: 8.171
Authors: E Lahner; C Bordi; E Di Giulio; P Caruana; G D'Ambra; M Milione; C Grossi; G Delle Fave; B Annibale Journal: Aliment Pharmacol Ther Date: 2002-03 Impact factor: 8.171
Authors: M Dinis-Ribeiro; C Lopes; A da Costa-Pereira; M Guilherme; J Barbosa; H Lomba-Viana; R Silva; L Moreira-Dias Journal: J Clin Pathol Date: 2004-02 Impact factor: 3.411
Authors: Irene Coati; Matteo Fassan; Fabio Farinati; David Y Graham; Robert M Genta; Massimo Rugge Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742
Authors: Francesco Cicone; Annalisa Papa; Chiara Lauri; Anna Tofani; Camilla Virili; Marco Centanni; Francesco Scopinaro; Bruno Annibale Journal: Endocrine Date: 2014-09-12 Impact factor: 3.633
Authors: S Felder; H Jann; R Arsenic; T Denecke; V Prasad; B Knappe-Drzikova; S Maasberg; B Wiedenmann; M Pavel; A Pascher; U F Pape Journal: Endocr Relat Cancer Date: 2019-09 Impact factor: 5.678
Authors: Maria Rinzivillo; Francesco Panzuto; Gianluca Esposito; Edith Lahner; Alberto Signore; Bruno Annibale Journal: J Clin Med Date: 2022-03-16 Impact factor: 4.241